相关实验视频
Updated: Jun 26, 2025

05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
17.8K
福西诺普利:与艾滋病毒相关的脏病 (HIVAN)
Joyce A Generali1, Dennis J Cada2
1Hospital Pharmacy, and Emeritus, Department of Pharmacy Practice, University of Kansas, School of Pharmacy, Kansas City/Lawrence, Kansas.
Hospital pharmacy
|May 15, 2024
概括
该资源有助于医疗保健专业人员快速找到和评估非标签药物用途. 它指导临床医生确定未经批准的药物应用在患者护理场景中的合理性.
科学领域:
- 药房实践 在药房实践中
- 临床药理学 临床药理学
- 药物信息 药物信息
背景情况:
- 非标签药物使用是指对未经美国食品和药物管理局 (FDA) 等监管机构批准的疾病开处方药物.
- 实践者需要可靠的资源来应对未经批准的药物指示的复杂性.
- 现有的文献可能是分散的,这使得评估非标签药物应用的证据具有挑战性.
研究的目的:
- 提供面向实践者的资源,提供关于非标签药物使用的信息.
- 为了使医疗保健专业人员能够有效地识别未经批准的药物指示的已发表研究.
- 帮助临床医生确定患者护理中特定非标签药物使用的合理性.
主要方法:
- 从出版物"非标签药物事实"中提取相关信息.
- 编制关于非标签药物应用的科学文献指南.
- 组织引用以引导用户使用全面的文献,以便明智作出决策.
主要成果:
- 介绍了一个结构化的指南,用于访问和评估非标签药物信息.
- 该资源有助于识别支持或反驳非标签药物使用的已发表研究.
- 临床医生可以利用本指南来评估特定未经批准的药物指示的证据基础.
结论:
- "非标签药物事实"是医疗保健专业人员管理未经批准的药物使用的宝贵工具.
- 该指南增强了临床医生对非标签处方做出基于证据的决策的能力.
- 它通过提供相关科学文献的访问来促进合理的药物治疗.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Renal Failure: Dose Adjustments
85
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
85
Antihypertensive Drugs: Direct Renin Inhibitors
601
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
601
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
620
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
620
Heart Failure Drugs: Diuretics
367
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
367
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146

